MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Tobira Therapeutics Company Profile (NASDAQ:TBRA)

Consensus Ratings for Tobira Therapeutics (NASDAQ:TBRA) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.33 (41.79% upside)

Analysts' Ratings History for Tobira Therapeutics (NASDAQ:TBRA)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Leerink SwannReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2015WedbushReiterated RatingUnderperform$1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014Jefferies GroupReiterated RatingHold$1.50 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2014Deutsche BankDowngradeBuy -> Hold$14.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2014Needham & Company LLCDowngradeBuy -> Hold$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/3/2014BMO Capital MarketsDowngradeOutperform -> Underperform$1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Tobira Therapeutics (NASDAQ:TBRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q116($0.53)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.52)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($1.00)($1.22)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.99)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.45)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.51)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.62)($1.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.43)($1.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Tobira Therapeutics (NASDAQ:TBRA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Tobira Therapeutics (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Tobira Therapeutics (NASDAQ:TBRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016A/S NovoMajor ShareholderSell187,500$10.37$1,944,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016A/S NovoMajor ShareholderSell190,000$6.80$1,292,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015A/S Novomajor shareholderSell225,000$9.79$2,202,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015A/S NovoMajor ShareholderBuy838,041$10.62$8,899,995.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Parters Vii L P DomainMajor ShareholderBuy277,777$10.62$2,949,991.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2014Robert Kierlinmajor shareholderBuy575,000$6.00$3,450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Robert Kierlinmajor shareholderBuy400,000$5.00$2,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2013Raphael WisniewskiDirectorBuy1,215,708$4.00$4,862,832.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2013Rmi Investments S.A.R.L.Major ShareholderBuy3,866,529$4.00$15,466,116.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Tobira Therapeutics (NASDAQ:TBRA)
DateHeadline
06/27/16 06:37 PMTobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH
06/27/16 03:51 PMTobira's Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH - [at noodls] - --Data Published in the Journal PLOS ONE-- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc.(NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development ...
06/17/16 06:24 PMTobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology
06/16/16 03:59 PMTobira's Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology - [at noodls] - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc.(NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for ...
06/06/16 07:35 AMTobira Therapeutics (TBRA) in Focus: Stock Up 6.4% in Session -
06/01/16 09:43 AMSum Up The Parts: Russell 2000 Has 12% Upside - Three of IWM's underlying holdings with notable upside to their analyst target prices are Tobira Therapeutics Inc (Symbol: TBRA), Civeo Corp (Symbol: CVEO), and MyoKardia Inc (Symbol: MYOK). Although TBRA has traded at a recent price of $9.25/share ...
05/31/16 08:12 AMTobira Therapeutics to Participate in Two Conferences in June - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 31, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences ...
05/17/16 12:04 PMTOBIRA THERAPEUTICS, INC. Financials -
05/13/16 08:58 AMTobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 13, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and ...
05/09/16 03:18 PMTobira Therapeutics Reports First Quarter 2016 Financial and Business Results - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 9, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments ...
05/09/16 03:17 PMTobira reports 1Q loss -
05/09/16 06:07 AMQ1 2016 Tobira Therapeutics Inc Earnings Release - After Market Close -
05/02/16 08:30 AMTobira Therapeutics Announces Date of 2016 First Quarter Financial Results and Conference Call - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 2, 2016 (GLOBE NEWSWIRE) -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel ...
05/02/16 08:10 AMTobira Announces Interim 12-week Results from the ORION Study - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 2, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments ...
04/21/16 03:21 PMTobira Announces Upcoming Presentations on Biomarkers for NASH at Two Scientific Meetings - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel ...
03/27/16 01:58 PMTobira Therapeutics Incorporated (NASDAQ:TBRA) Sellers Increased By 12.37% Their Shorts - Clinton Financial - Tobira Therapeutics Incorporated (NASDAQ:TBRA) Sellers Increased By 12.37% Their ShortsClinton FinancialThe short interest to Tobira Therapeutics Incorporated's float is 5.28%. The stock decreased 6.33% or $0.51 on March 24, hitting $7.55. About 100,861 shares traded hands or 134.24% up from the average. Tobira Therapeutics Inc (NASDAQ:TBRA) has ...and more »
03/23/16 01:48 PMTobira Therapeutics Inc Rises A lot Today, Is Now One of The Best Performer - RiversideGazette.com - Tobira Therapeutics Inc Rises A lot Today, Is Now One of The Best PerformerRiversideGazette.comThe stock of Tobira Therapeutics Inc (NASDAQ:TBRA) is a huge mover today! The stock increased 5.38% or $0.45 during the last trading session, hitting $8.82. About 105,244 shares traded hands or 161.42% up from the average. Tobira Therapeutics Inc ...
03/22/16 07:35 AMTobira Therapeutics (TBRA) in Focus: Stock Up 5.4% in Session -
03/14/16 02:04 PMRevenue Update on Tobira Therapeutics Inc(NASDAQ:TBRA) - Street Edition - Revenue Update on Tobira Therapeutics Inc(NASDAQ:TBRA)Street EditionTobira Therapeutics Inc(NASDAQ:TBRA) announced the earnings results for Fiscal Year 2015 and Q4. The results came in during After-hours on Mar 3, 2016. Earnings per share were $-0.50. Analysts had estimated an EPS of $-0.52. Tobira Therapeutics Inc ...
03/10/16 01:42 PMRecent Broker Updates On Tobira Therapeutics, Inc. (TBRA) - Risers & Fallers - Recent Broker Updates On Tobira Therapeutics, Inc. (TBRA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Tobira Therapeutics, Inc. (TBRA). The latest broker reports which are currently outstanding on Thursday 10th of March state 1 analyst has a rating of “strong buy”, 1 ...
03/10/16 01:42 PMTobira Therapeutics' (TBRA) CENTAUR Phase 2b Study Design, Rationale Published in Contemporary Clinical Trials - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that the description of the fully-enrolled CENTAUR Phase 2b clinical trial design has been accepted as a ...
03/09/16 01:46 PMTobira Therapeutics' (TBRA) CENTAUR Phase 2b Study Design, Rationale Published in Contemporary Clinical Trials - StreetInsider.com - Tobira Therapeutics' (TBRA) CENTAUR Phase 2b Study Design, Rationale Published in Contemporary Clinical TrialsStreetInsider.comTobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that the description of the fully-enrolled CENTAUR Phase 2b clinical trial design has been accepted as a manuscript and published online in the journal Contemporary Clinical Trials. Available at: ...and more »
03/09/16 07:30 AMTobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., March 9, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that the description of the fully-enrolled CENTAUR Phase 2b clinical trial design has been accepted as a manuscript and published online in the journal Contemporary Clinical Trials. "The treatment of NASH is a high unmet medical need as NASH is currently the second leading cause of liver transplant in the U.S. and is predicted to become the leading cause by 2020," said Scott Friedman, M.D., Chief, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai.
03/04/16 01:09 PMTobira Therapeutics Reports Fourth Quarter 2015 Financial and Year-End Business Results - SOUTH SAN FRANCISCO, Calif., March 3, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic ...
03/04/16 01:09 PMTobira Therapeutics : reports 4Q loss - SOUTH SAN FRANCISCO, Calif. (AP) _ Tobira Therapeutics Inc. (TBRA) on Thursday reported a loss of $9.4 million in its fourth quarter. The South San Francisco, California-based company said it had a loss of 50 cents per share. For the year, the company ...
03/04/16 01:09 PMTobira Therapeutics Inc. posts loss of $9.4 million in fourth quarter - SOUTH SAN FRANCISCO, Calif. - SOUTH SAN FRANCISCO, Calif. (AP) _ Tobira Therapeutics Inc. (TBRA) on Thursday reported a loss of $9.4 million in its fourth quarter. The South San Francisco, California-based company said it had a loss of 50 cents per share.
03/03/16 05:03 PMTobira reports 4Q loss -
03/03/16 03:50 PMTOBIRA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/03/16 03:18 PM4:18 pm Tobira Therapeutics reports Q4 results, provides clinical update -
03/03/16 01:29 PMStock HC in Focus : Tobira Therapeutics (TBRA), K2M Group (KTWO), Sunshine Heart (SSH) - share market updates (press release) - share market updates (press release)Stock HC in Focus : Tobira Therapeutics (TBRA), K2M Group (KTWO), Sunshine Heart (SSH)share market updates (press release)Shares of Tobira Therapeutics Inc (NASDAQ:TBRA) ended Wednesday session in red amid volatile trading. The shares closed down -0.04 points or -0.57% at $6.96 with 152,052.00 shares getting traded. Post opening the session at $6.95, the shares hit an ...and more »
03/03/16 01:29 PMWatch List: Tobira Therapeutics Inc (TBRA) - CWRU Observer - Watch List: Tobira Therapeutics Inc (TBRA)CWRU ObserverTobira Therapeutics Inc (NASDAQ:TBRA) is expected to report 4th quarter earnings after the close on Mar 3, 2016, with a conference call scheduled for 4:30PM EST. Trecora Resources primarily manufactures and sells various specialty petrochemical ...
03/03/16 06:07 AMQ4 2015 Tobira Therapeutics Inc Earnings Release - After Market Close -
03/02/16 01:07 PMTobira Therapeutics Incorporated (NASDAQ:TBRA) Short Interest Increased By 23.36% - Business Standard Tribune - Tobira Therapeutics Incorporated (NASDAQ:TBRA) Short Interest Increased By 23.36%Business Standard TribuneThe short interest to Tobira Therapeutics Incorporated's float is 5.2%. The stock decreased 1.13% or $0.08 during the last trading session, hitting $7. About 63,104 shares traded hands or 55.97% up from the average. Tobira Therapeutics Inc (NASDAQ:TBRA ...
03/01/16 07:30 AMTobira Therapeutics to Participate in Two Conferences in March - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., March 1, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences ...
02/26/16 12:58 PMChanges To Broker Targets On Tobira Therapeutics, Inc. (TBRA) - Share Trading News - Changes To Broker Targets On Tobira Therapeutics, Inc. (TBRA)Share Trading NewsTobira Therapeutics, Inc., formerly Regado BioSciences, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV).Tobira Therapeutics Incorporated (NASDAQ:TBRA) Sellers Increased By 2.46% Their ShortsSmallCapWired.comall 2 news articles »
02/25/16 01:01 PMTobira Therapeutics, Inc. (TBRA) Recent Analyst Updates - Risers & Fallers - Tobira Therapeutics, Inc. (TBRA) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Tobira Therapeutics, Inc. (TBRA). According to the latest broker reports outstanding on Wednesday 24th of February, 0 analysts have a rating of “strong buy”, 0 ...
02/22/16 03:05 PMTobira Therapeutics Announces Date of 2015 Fourth Quarter Financial Results and Conference Call - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif. -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a biopharmaceutical company developing novel treatments for nonalcoholic steatohepatitis (NASH), and other serious immuno-inflammatory ...
02/22/16 12:39 PMEarnings Per Share Expected to Rise for Tobira Therapeutics Inc (TBRA) - RiversideGazette.com - Earnings Per Share Expected to Rise for Tobira Therapeutics Inc (TBRA)RiversideGazette.comWall Street await Tobira Therapeutics Inc (NASDAQ:TBRA) to release earnings on February, 23. After releasing $-0.60 EPS for the previous quarter, Tobira Therapeutics Inc's analysts now forecasts -15.00% EPS growth. The stock decreased 2.11% or $0.15 ...Tobira Therapeutics Incorporated (NASDAQ:TBRA) Shorted Shares Increased 2.46% After Market SellingStock CallerEye Catching Stocks: Tobira Therapeutics, Inc. (NASDAQ:TBRA), Relypsa, Inc. (NASDAQ:RLYP), Bank of America ...KC Registerall 3 news articles »
02/18/16 12:38 PMTobira Therapeutics Incorporated (NASDAQ:TBRA) Shorted Shares Increased 2.46% After Market Selling - fdanewsalert.com - Tobira Therapeutics Incorporated (NASDAQ:TBRA) Shorted Shares Increased 2.46% After Market Sellingfdanewsalert.comThe short interest to Tobira Therapeutics Incorporated's float is 4.16%. The stock increased 1.77% or $0.13 during the last trading session, hitting $7.47. About 27,839 shares traded hands. Tobira Therapeutics Inc (NASDAQ:TBRA) has declined 57.84 ...Zacks: Analysts Anticipate Tobira Therapeutics Inc (NASDAQ:TBRA) to Post -$0.51 Earnings Per ShareThe Vista Voiceall 2 news articles »
02/17/16 12:45 PMGenfit's NASH Phase 2b Results Are Published And Confirm The Biotech's Lead - Seeking Alpha - Seeking AlphaGenfit's NASH Phase 2b Results Are Published And Confirm The Biotech's LeadSeeking AlphaSeveral companies are currently developing NASH-targeted drugs in the clinic, including Gilead (NASDAQ:GILD), Novo Nordisk (NYSE:NVO), Tobira (NASDAQ:TBRA), Galmed (NASDAQ:GLMD) and Conatus (NASDAQ:CNAT), but until now only Intercept ...
02/10/16 12:29 PMBLPH Heartened, More Trouble For CTIC, Remicade Biosimilar Gets FDA Panel Nod - Nasdaq - BLPH Heartened, More Trouble For CTIC, Remicade Biosimilar Gets FDA Panel NodNasdaqThe company also plans to report additional clinical data from a phase II study of PBI-4050 in type 2 diabetes patients this quarter. PLI.TO closed Tuesday's trading at C$2.11, down 5.38%. Tobira Therapeutics Inc. (TBRA) has completed recruitment in ...and more »
02/10/16 12:29 PMEarnings Per Share Increase Expected for Tobira Therapeutics Inc (TBRA) - OctaFinance.com - Earnings Per Share Increase Expected for Tobira Therapeutics Inc (TBRA)OctaFinance.comAnalysts await Tobira Therapeutics Inc (NASDAQ:TBRA) to reports earnings on February, 9. After $-0.60 actual earnings per share reported by Tobira Therapeutics Inc for the previous quarter, Wall Street now forecasts -15.00 % EPS growth. The stock ...
02/09/16 12:26 PMTobira Therapeutics (TBRA) Completes Recruitment for ORION Phase 2a Study in NAFLD - StreetInsider.com - Tobira Therapeutics (TBRA) Completes Recruitment for ORION Phase 2a Study in NAFLDStreetInsider.comTobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, announced that it has completed recruitment for ...and more »
02/09/16 12:26 PMTobira Therapeutics (TBRA) Completes Recruitment for ORION Phase 2a Study in NAFLD - Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, announced that it has completed recruitment for the ...
02/09/16 07:30 AMTobira Therapeutics Completes Patient Recruitment for ORION Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease - [PR Newswire] - SOUTH SAN FRANCISCO, Calif., Feb. 9, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, announced that it has completed recruitment for the Phase 2a ORION study. ORION is a randomized, double-blind, placebo-controlled study exploring the metabolic effects of cenicriviroc (CVC) in obese adults (BMI greater than or equal to 30 kg/m2) with prediabetes or diabetes and suspected non-alcoholic fatty liver disease (NAFLD). The primary outcome of ORION will measure changes in insulin sensitivity in peripheral and adipose tissue over a 24-week period and will include an interim analysis at 12 weeks.
02/08/16 12:38 PMLatest Analysts Reports On Tobira Therapeutics, Inc. (TBRA) - Risers & Fallers - Latest Analysts Reports On Tobira Therapeutics, Inc. (TBRA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Tobira Therapeutics, Inc. (TBRA). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 ...What to Expect from Tobira Therapeutics Inc (TBRA) EPS?WallStreet.orgall 2 news articles »
02/04/16 12:39 PMTobira Therapeutics Inc Sets All-Time Low; Strong Momentum for Sellers - WallStreet.org - Tobira Therapeutics Inc Sets All-Time Low; Strong Momentum for SellersWallStreet.orgThe stock of Tobira Therapeutics Inc (NASDAQ:TBRA) reached all time low today, Feb, 4 and still has $5.54 target or 13.00% below today's $6.37 share price. This indicates more downside for the $69.92M company. This technical setup was reported by ...and more »
02/01/16 12:27 PMTobira Therapeutics to Participate in Two Conferences in February - PR Newswire (press release) - Tobira Therapeutics to Participate in Two Conferences in FebruaryPR Newswire (press release)SOUTH SAN FRANCISCO, Calif., Feb. 1, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences in February. 18th Annual BIO CEO ...and more »
02/01/16 07:20 AMTobira Therapeutics to Participate in Two Conferences in February - [at noodls] - , /PRNewswire/ -- (: TBRA) today announced that company management will present an overview of the company at the following conferences in February. ... This is an abstract of the original noodl. To continue ...
01/29/16 01:14 PMPrice Target Update On Tobira Therapeutics, Inc. (TBRA) - Risers & Fallers - Price Target Update On Tobira Therapeutics, Inc. (TBRA)Risers & Fallers11/13/2015 – Cowen began new coverage on Tobira Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 21 price target on the stock. 10/23/2015 – Leerink Swann began new coverage on Tobira Therapeutics, Inc. giving the ...
About Tobira Therapeutics

Tobira Therapeutics logoTobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBRA
  • CUSIP:
Key Metrics:
  • Previous Close: $14.34
  • 50 Day Moving Average: $9.93
  • 200 Day Moving Average: $8.48
  • P/E Ratio: N/A
  • P/E Growth: 0.12
  • Market Cap: $265.86M
  • Current Quarter EPS Consensus Estimate: $-2.42 EPS
Additional Links:
Tobira Therapeutics (NASDAQ:TBRA) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha